-
Mashup Score: 518-gene urine test may reduce unnecessary prostate biopsies - 18 hour(s) ago
The MPS2 models demonstrated negative predictive values of 95% to 99% for cancers of grade group 2 or higher and of 99% for cancers of grade group 3 or higher.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1
“And [3 out of 5] of those patients who were initially deemed to go on to nephroureterectomy were able to be converted to endoscopic management,” says Surena F. Matin, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1
“I think in terms of the 2 large tool sets we have, biomarker testing through urine or blood tests and imaging. I think both are only going to get better,” says Jeffrey Tosoian, MD, MPH.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 2
“What we find here was that of the patients who had FGFR3 alterations, 67% of them had tumors that responded,” says Surena F. Matin, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0Agreement reached to expand distribution of avanafil for ED - 2 day(s) ago
Petros also announced that it has received positive feedback from the FDA after the agency’s informal review of Petros’ technology component for self-selection.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 3FDA accepts IND application for RAG-01 in NMIBC - 2 day(s) ago
The clearance of the IND application for RAG-01 will initiate the launch of clinical trials in the US.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 3
A decision regarding EU marketing authorization is expected by June 2024.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 192024 AUA preview: Dr. Wymer on top research in stone disease - 2 day(s) ago
Kevin M. Wymer, MD, highlights 11 studies in stone disease being presented at the 2024 American Urological Association Annual Meeting.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1
“ARO-HIF2’s ability to target cancer cells, disrupting a key tumor-driving mechanism, illustrates the potential of siRNA technology in oncology,” says James Brugarolas, MD, PhD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 162024 AUA preview: Dr. Elterman on key research in BPH - 3 day(s) ago
Dean S. Elterman, MD, MSc, FRCSC, highlights several studies in BPH being presented at the 2024 AUA Annual Meeting.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
An 18-gene urine test demonstrated higher diagnostic accuracy for high-grade prostate cancer than existing biomarker tests, suggesting that the urinary panel may help avoid unnecessary biopsies. #pcsm #cancerresearch @UMichUrology Read more: https://t.co/DAswxfKWtN